Sponsored Symposia

Add Sponsored Symposia to your schedule and connect with industry supporters to learn about developments and technologies in the field of cancer immunotherapy.

Sponsored Symposia content and views expressed therein are those of the sponsoring organization and not of SITC.

Click a button to view each company:

Thursday, Nov. 10

10x Genomics

Thursday, Nov. 10, 2022  | 12-1 p.m.  |  Room 156, BCEC

Immunogenomic determinants of response and resistance to PD-1 blockade
Kellie Smith, PhD, Johns Hopkins University

Multiomic Profiling of Immune Diversity, Cell by Cell
Jose Jacob, MS, 10x Genomics

NanoString Technologies

Thursday, Nov. 10, 2022 | 11:40 a.m.-1:10 p.m. | Room 157, BCEC

Expanding the Power of Spatial Biology

Hear from thought leaders in Spatial Biology at NanoString’s Spatial Symposium. This session will showcase the most comprehensive spatial biology solutions from samples to insight.  Leverage the leading high-plex, multiomics spatial platforms from single cell resolution to whole transcriptome and spatial proteome for biomarker discovery and pathway analysis and unlock the tumor microenvironment in FFPE tissues.  All spatial data can be analyzed, stored and shared using a cloud-based, secure and scalable informatic solution, AtoMx Spatial Informatics Platform.

Learn more about the range of spatial biology solutions offered by NanoString and a roadmap for the future development of the AtoMx Spatial Informatics Platform, CosMx Spatial Molecular Imager, and GeoMx Digital Spatial Profiler.

Pelotonia Institute for Immuno-Oncology OSU Comprehensive Cancer Center

Thursday, Nov. 10, 2022 | 12-1 p.m. | Exhibit Hall Stage, BCEC

Sex Bias and Cancer Immunotherapy

This symposium will address the striking sex-dependent discrepancies in incidence, progression, response to treatment, and survival outcomes for patients with cancers stemming from non-reproductive organs, such as bladder, prostate, and brain cancer. Sex bias in cancer and response to immunotherapy are phenomena that have puzzled the scientific community for decades. Recently, our understanding about the role of sex in tumor immunology has advanced, providing opportunities to improve targeted therapies. With this symposium, we will present recent updates in the field of immuno-oncology, immunotherapy, and disease outcomes within the context of sex-based disease discrepancies. This symposium will give attendees a unique opportunity to learn from top researchers studying the intersection between sex, tumor immunology, and translational therapeutics.

Akoya Biosciences

Thursday, Nov. 10, 2022 | 7:30-9 p.m. | Room 156, BCEC

Supercharging Spatial Signature Development: Predictive Biomarkers for the Ever-Changing Immunotherapy Landscape

The emergence of new immunotherapies as the first line of treatment for cancer, necessitates the development of clinically useful biomarkers to select responders that will be critical for the advancement of such treatments. Join us to learn about spatial signatures, biomarkers based on spatial relationships and protein co-expression on specific cellular subsets that are assessed within the context of the tumor immune microenvironment (TiME), which have demonstrated higher accuracy in predicting response to immunotherapies. Learn from speakers about Akoya’s new multiplex panels based on novel protein chemistry that can accelerate the development of spatial signatures, simplifying the pathway to improved stratification to immunotherapy response.

Clinical Care Options

Thursday, Nov. 10, 2022 | 7:30-9 p.m. | Room 157, BCEC

Lung Cancer Immunotherapy: Improving Patient Outcomes Across the Disease Continuum

Join us in person or online for this live CME symposium at SITC 2022 Annual Meeting to hear expert insights on best practices for the use of immune checkpoint inhibitor therapy for patients with NSCLC. Click here to view this symposia. 

Discovery Life Sciences

Thursday, Nov. 10, 2022 | 7:30-9 p.m. | Room 206, BCEC

Multi-Omic Analysis of Matched Human Biospecimens to Inform Drug and Biomarker Development

Friday, Nov. 11


Friday, Nov. 11, 2022 | 12-1 p.m. | Room 206, BCEC

Approved Treatment Option for Unresectable Hepatocellular Carcinoma


Friday, Nov. 11, 2022 | 12-1 p.m. | Exhibit Hall Stage, BCEC

Adaptive Immune Repertoire Profiling: Research Success Stories

Creative Educational Concepts

Friday, Nov. 11, 2022 | 12-1 p.m. | Room 157, BCEC

Harnessing the Power of Immunotherapy in HCC and BTC: An Expert Exploration of the Past, Present, and Future of Checkpoint Inhibition

This session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) management calculus. Faculty will highlight the paradigmatic change ICIs have achieved, emphasize key teaching points for real-world use, and evaluate adaptive clinical trial designs and study schemas being used to investigate ICI-based treatment regimens in HCC and BTC on a prospective basis.

Merck & Co., Inc.

Friday, Nov. 11, 2022 | 12-1 p.m. | Room 156, BCEC

A Treatment Option for Certain Patients With Advanced Gastric or GEJ Cancer

  • Provide an overview of gastric cancer
  • Review the clinical data for a treatment option in certain patients with advanced gastric or GEJ cancer
  • Discuss a hypothetical case of a patient with metastatic gastric adenocarcinoma


Friday, Nov. 11, 2022 | 7-7:30 p.m. | Exhibit Hall Stage, BCEC

Applications of personalized ctDNA monitoring to optimize immunotherapy treatment decisions


Friday, Nov. 11, 2022 | 7-8:30 p.m. | Room 156, BCEC

Veracyte Biopharma Atlas: A TME-based multi-omics analysis for predictive modelling

Veracyte and invited speakers will introduce a reference database in DLBCL. The ambitious program assesses thousands of parameters using an unsupervised multi-omics and multimodal approach. The database may be used to generate maps and clusters that can be used for patient group identification and clinical outcome interpretation.

After the talk, attendees will have the opportunity to ask questions and network with the Veracyte and invited speakers.